The CEO of biotech company Genfit told CNBC that the markets are overreacting to the results of its NASH study.» Read More
CNBC's Meg Tirrell reports the Drug Enforcement Administration is changing the rules around pain drugs like Vicodin. The drugs will be deemed "schedule 2 substances," versus the less restrictive "schedule 3."
CNBC's Meg Tirrell reports which biotech drug developments investors are excited about.
Zafgen CEO Tom Hughes discusses the company's dedication to tackle obesity, with CNBC's Meg Tirrell. Hughes says the new drug works to impact the way the body handles fat.
CNBC's Morgan Brennan runs through today's big biotech movers.
Barbara Ryan, FTI Consulting, discusses the tremendous amount of innovation within in the biotech sector and why the segment is attractive.
CNBC's Meg Tirrell looks at companies in the early stages of Ebola drug and vaccine trials.
CNBC's Meg Tirrell reports both Merck and Pfizer beat earnings expectations amid patent expirations.
"The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.
CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.
CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.
Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.
Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.
After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.
CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.
Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.
The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.
CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.
CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.
Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.
Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.